What is Psilera?
Founded in 2019 and operating under DEA approval, Psilera is at the forefront of psychedelic-based biotechnology, aiming to innovate therapies for mood, cognitive, and addiction disorders. The company's leadership comprises seasoned professionals from the pharmaceutical and science-driven cannabis industries. Psilera's approach is rooted in robust research and a patient-centric philosophy, focusing on developing novel compounds and formulations. Their work involves leveraging strengths in research to create a unique computational database, positioning them to address unmet needs in mental healthcare.
How much funding has Psilera raised?
Psilera has raised a total of $11.3M across 2 funding rounds:
Angel/Seed
$2.5M
Seed
$8.8M
Angel/Seed (2021): $2.5M, investors not publicly disclosed
Seed (2026): $8.8M, investors not publicly disclosed
What's next for Psilera?
With the recent influx of major strategic investment, Psilera is poised for significant expansion and advancement in its research and development initiatives. The company's focus on repurposing natural psychoactive products as building blocks for new medicines, particularly for mood, cognitive, and addiction disorders, aligns with a growing interest in alternative therapeutic approaches. This capital infusion will likely fuel the progression of their proprietary drug pipeline, enhance their computational database capabilities, and support efforts to navigate regulatory pathways, including DEA approval, to bring these innovative therapies to patients.
See full Psilera company page
